These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
527 related articles for article (PubMed ID: 30334995)
1. Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: A meta-analysis. Lee JH; Jeong H; Choi JW; Oh HE; Kim YS Medicine (Baltimore); 2018 Oct; 97(42):e12862. PubMed ID: 30334995 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes. Koca E; Kuzan TY; Dizdar O; Babacan T; Sahin I; Ararat E; Altundag K Med Oncol; 2013; 30(3):615. PubMed ID: 23729267 [TBL] [Abstract][Full Text] [Related]
3. Mutation profiling in the PIK3CA, TP53, and CDKN2A genes in circulating free DNA and impalpable breast lesions. Delmonico L; Costa MASM; Fournier MV; Romano SO; Nascimento CMD; Barbosa AS; Moreira ADS; Scherrer LR; Ornellas MHF; Alves G Ann Diagn Pathol; 2019 Apr; 39():30-35. PubMed ID: 30634138 [TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients. Zavarykina TM; Lomskova PK; Pronina IV; Khokhlova SV; Stenina MB; Sukhikh GT Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069396 [TBL] [Abstract][Full Text] [Related]
5. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis. Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112 [TBL] [Abstract][Full Text] [Related]
6. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival. Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248 [TBL] [Abstract][Full Text] [Related]
7. Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application. Casas-Arozamena C; Vilar A; Cueva J; Arias E; Sampayo V; Diaz E; Oltra SS; Moiola CP; Cabrera S; Cortegoso A; Curiel T; Abalo A; Pamies Serrano M; Domingo S; Padilla-Iserte P; Arnaez de la Cruz M; Hernández A; García-Pineda V; Ruiz-Bañobre J; López R; Matias-Guiu X; Colás E; Gil-Moreno A; Abal M; Moreno-Bueno G; Muinelo-Romay L J Exp Clin Cancer Res; 2024 Sep; 43(1):264. PubMed ID: 39304963 [TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis. Nader-Marta G; Monteforte M; Agostinetto E; Cinquini M; Martins-Branco D; Langouo M; Llombart-Cusac A; Cortés J; Ignatiadis M; Torri V; Apolone G; Cappelletti V; Pruneri G; de Azambuja E; Di Cosimo S ESMO Open; 2024 Mar; 9(3):102390. PubMed ID: 38460249 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432 [TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of δ-like ligand 4 contributes significantly to axillary lymph node metastasis and predicts postoperative outcome in breast cancer. Xiao M; Yang S; Ning X; Huang Y Hum Pathol; 2014 Nov; 45(11):2302-10. PubMed ID: 25260720 [TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA and Survival in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. Dickinson K; Sharma A; Agnihotram RV; Altuntur S; Park M; Meterissian S; Burnier JV JAMA Netw Open; 2024 Sep; 7(9):e2431722. PubMed ID: 39235812 [TBL] [Abstract][Full Text] [Related]
12. Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer. Yao MS; Kurland BF; Smith AH; Schubert EK; Dunnwald LK; Byrd DR; Mankoff DA Ann Surg Oncol; 2007 Oct; 14(10):2985-93. PubMed ID: 17564747 [TBL] [Abstract][Full Text] [Related]
13. Correlation Between Raf/MEK/ERK Signaling Pathway and Clinicopathological Features and Prognosis for Patients With Breast Cancer Having Axillary Lymph Node Metastasis. Shao GL; Wang MC; Fan XL; Zhong L; Ji SF; Sang G; Wang S Technol Cancer Res Treat; 2018 Jan; 17():1533034617754024. PubMed ID: 29529946 [TBL] [Abstract][Full Text] [Related]
14. Liquid biopsy in breast cancer: A comprehensive review. Alimirzaie S; Bagherzadeh M; Akbari MR Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931 [TBL] [Abstract][Full Text] [Related]
15. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. de Boer M; van Dijck JA; Bult P; Borm GF; Tjan-Heijnen VC J Natl Cancer Inst; 2010 Mar; 102(6):410-25. PubMed ID: 20190185 [TBL] [Abstract][Full Text] [Related]
16. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment. Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494 [TBL] [Abstract][Full Text] [Related]
17. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial]. Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111 [TBL] [Abstract][Full Text] [Related]
18. Impact of axillary lymph node dissection on breast cancer outcome in clinically node negative patients: a systematic review and meta-analysis. Sanghani M; Balk EM; Cady B Cancer; 2009 Apr; 115(8):1613-20. PubMed ID: 19199349 [TBL] [Abstract][Full Text] [Related]
19. The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis. Tan G; Chu C; Gui X; Li J; Chen Q Medicine (Baltimore); 2018 Mar; 97(13):e0197. PubMed ID: 29595655 [TBL] [Abstract][Full Text] [Related]
20. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer. Yang X; Zhang K; Zhang C; Peng R; Sun C BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]